Krystal Biotech, Inc.
NASDAQ:KRYSBiotechnology
+$18.29 today
- Market cap
- $9.34B
- Beta
- 0.53
- P/E (TTM)
- 44.5
- EPS (TTM)
- $7.68
Volume 0.35M
Average 0.29M
KRYS Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Krystal Biotech, Inc.NASDAQ: KRYS
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow grows in line with its trailing trend
Q2 FY2026 free cash flow of $71.22M rose 40.1% year over year, ahead of the +39.0% change in trailing-twelve-month free cash flow. Sequentially, it fell 2.7% from the prior quarter.
Context
- Free cash flow amounted to 48.5% of revenue in FY2025, up 7.5 pp from a year earlier.
- Free cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +40.1% holds above the trailing-twelve-month pace of +39.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 188.91M USD
- Year-over-year change
- +58.5%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 188.91M | +58.5% |
| FY2024 | 2024-12-31 | 119.18M | +218.5% |
| FY2023 | 2023-12-31 | (100.6M) | +34.5% |
| FY2022 | 2022-12-31 | (153.55M) | -32.1% |
| FY2021 | 2021-12-31 | (116.27M) | — |
Free Cash Flow vs competitors
How KRYS compares with its peers on the latest reported figures
- KRYS's LTM Jun 2026 free cash flow of $257.78M is the largest of the 6 companies compared; the peer median is $133.64M.
- Its year-over-year change of +39.0% is the 2nd highest of 6, against a peer median of -15.6%.
- Free cash flow amounts to 58.5% of revenue for KRYS, versus a peer median of 269.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $257.78M | +39.0% | — | 58.5% | |
| LTM Mar 2026 | $236.4M | +171.9% | -19.0% | 269.2% | |
| LTM Mar 2026 | $179.8M | -15.6% | +0.7% | — | |
| LTM Mar 2026 | $133.64M | -40.3% | -22.5% | — | |
| LTM Mar 2026 | $85.24M | +35.3% | +24.6% | 586.2% | |
| LTM Mar 2026 | $2.34M | -97.9% | -24.8% | 2.9% | |
| Peer median (excluding KRYS) | $133.64M | -15.6% | -19.0% | 269.2% | |
Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (69.57M) | (139.98M) | 10.93M | 89.16M | 204.83M |
| Depreciation & Amortization | 2.77M | 4.05M | 5.01M | 6.71M | 6.55M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (22.85M) |
| Stock-Based Compensation | 15.32M | 33.23M | 39.93M | 49.13M | 54.51M |
| Change in Working Capital | 2.05M | 2.81M | (37.88M) | (14.46M) | (36.42M) |
| Accounts Receivables | 0 | 0 | (42.04M) | (62.71M) | (22.12M) |
| Inventory | 0 | 0 | (4.48M) | (11.91M) | (6.29M) |
| Accounts Payables | 712K | (1.25M) | (101K) | 1.01M | 826K |
| Other Working Capital | 1.34M | 4.07M | 8.73M | 59.15M | (8.84M) |
| Other Non-Cash Items | 1.49M | (690K) | (106.79M) | (7.12M) | (5.77M) |
| Operating Cash Flow | (47.94M) | (100.57M) | (88.8M) | 123.42M | 200.87M |
| Capital Expenditures | (68.34M) | (52.98M) | (11.8M) | (4.24M) | (11.95M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 435K |
| Purchases of Investments | (190.46M) | (318.78M) | (508.78M) | (457.74M) | (422.54M) |
| Sales of Investments | 32.03M | 257.68M | 503.21M | 298.54M | 375.64M |
| Other Investing Activities | 0 | 0 | 100M | 0 | 0 |
| Investing Cash Flow | (226.77M) | (114.08M) | 82.64M | (163.44M) | (58.42M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 355.65M | 36M | 203.5M | 32.4M | 22.66M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.96M) | (649K) | (749K) | (5.39M) | (13.96M) |
| Financing Cash Flow | 347.69M | 35.35M | 202.75M | 27.01M | 8.71M |
| Effect of Forex Changes | 0 | (41K) | (156K) | (458K) | 286K |
| Net Change in Cash | 72.98M | (179.35M) | 196.43M | (13.46M) | 151.44M |
| Free Cash Flow | (116.27M) | (153.55M) | (100.6M) | 119.18M | 188.91M |
Krystal Biotech, Inc.
NASDAQ:KRYS
Intrinsic Alpha fair value
Locked
Current Price
$315.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.